Keyword
in
Collection
Date
to
Download Folder

0 items

Houston Voice, No. 1000, December 24, 1999
File 004
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 1000, December 24, 1999 - File 004. 1999-12-24. University of Houston Libraries. University of Houston Digital Library. Web. December 14, 2017. http://digital.lib.uh.edu/collection/montrose/item/6369/show/6343.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1999-12-24). Houston Voice, No. 1000, December 24, 1999 - File 004. Montrose Voice. University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/montrose/item/6369/show/6343

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 1000, December 24, 1999 - File 004, 1999-12-24, Montrose Voice, University of Houston Libraries, accessed December 14, 2017, http://digital.lib.uh.edu/collection/montrose/item/6369/show/6343.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 1000, December 24, 1999
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date December 24, 1999
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Rights In Copyright: This item is protected by copyright. Copyright to this resource is held by the creator or current rights holder, and the resource is provided here for educational purposes. It may not be reproduced or distributed in any format without permission of the copyright owner. Users assume full responsibility for any infringement of copyright or related rights.
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 004
Transcript HOUSTON VOICE • DECEMBER 24, 1999 .eHIV+, CRIXIVAN may help you live a longer, healthier life. 1 ■ HIGHLY EFFECTIVE THERAPY CRIXIVAN in combination with antiretroviral agents is a powerful protease inhibitor that fights HIV among the preferred treatments for HIV in federal healthcare guidelines.' CRIXIVAN can help reduce the chance of illnesses and death associated with HIV; CRIXIVAN can also help lower the amount of HIV in your body (called "viral load") and raise your CD4T-cell count, as shown in studies over a one-year period. Some patients may not experience these effects. CRIXWAN is not a cure for HIV or AIDS. ■ DURABLE RESULTS In a landmark study, over 90% of 31 patients receiving a combination of CRIXIVAN, AZT and 3TC reduced their serum viral load below the limit of detection after 24 weeks. Importantly the limited number of patients who chose to stay wrth the study for longer periods of time maintained these resufts through the one-year mark. In a separate study, 30% of 261 patients receiving dual therapy of CRIXIVAN and AZT had serum viral loads below the limit of detection at 48 weeks. In another landmark study, -43% of 40 patients receiving combination therapy with CRIXIVAN, AZT and 3TC had plasma viral loads below the limit of detection at 40 weeks. In this study of over 1,000 patients, the group of patients receiving CRIXIVAN along wrth 3TC and AZT achieved a reduction in deaths and AIDS-definmg illnesses over those taking 3TC and AZT alone. Overall, the number of deaths was inadequate to assess the impact of CRIXIVAN on survival. Blood viral loads were measured by available tests and the virus may still be present in other organ systems. m THINGS YOU SHOULD KNOW ABOUT CRIXIVAN CRIXIVAN can be taken with a light meal or on an empty stomach. Some patients treated with CRIXIVAN may develop kidney stones. For some, this can lead to more severe kidney problems, including kidney failure. Drinking at least 6 glasses of water each day may help reduce the chance of forming a kidney stone. Other side effects reported include rapid breakdown of red blood cells and liver problems. As wrth other protease inhibrtors, changes in body fat increased bleeding in some patients wrth hemophilia, and increased Wood sugar levels or diabetes have been reported. Additionally, severe muscle pain and weakness have occurred in patients also taking cholesterol-lowering medicines called "statins." There are some common medications and AIDS-related medications you should not take wrth CRIXIVAN. Discuss a\\ medications you are taking or plan to take wrth your doctor For more detailed information about CRIXIVAN, please read the information immediately following this advertisement ' Guidelines for the Use of Antiretroviral Agents in HIV-infected Adurts and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection. Department of Heafth and Human Services (DHHS), May 5. 1999. Remember to ask your doctor about CRIXIVAN. CRIXIVAN" S—bbIJK Capsules
File Name uhlib_31485329_n1000_003.jpg